CKX Stock Chart & Stats
€14.10
-€0.05(-0.61%)
At close: 4:00 PM EST
€14.10
-€0.05(-0.61%)
Day’s Range― - ―
52-Week Range€6.50 - €16.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€835.62M
Enterprise Value€673.55M
Total Cash (Recent Filing)€396.69M
Total Debt (Recent Filing)€232.02M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 05, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding50,649,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-17.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.70Price Target Upside32.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.7
Revenue Forecast (FY)€174.04M
Bulls Say, Bears Say
Bulls Say
Clinical And Commercial ScaleCryoport’s broad participation across 779 trials, including 94 Phase III programs, and support for 22 commercial therapies indicates meaningful embedded scale. This reach can support recurring logistics demand as therapies advance through development and commercial distribution.
Improving Operating PerformanceThe move to positive adjusted EBITDA and materially improved operating cash flow signals better operating execution and utilization. If maintained, these gains can strengthen internal funding capacity and provide a foundation for eventual improvement in overall profitability.
Life Science Services GrowthGrowth in Life Science Services, particularly the 25% increase in biostorage and bioservices, supports a more diversified recurring-services base. These offerings can deepen customer relationships and increase participation in complex therapy supply chains over time.
Bears Say
Persistent Losses And Cash BurnDespite improved operating cash flow, negative TTM earnings and free cash flow show that Cryoport is not yet consistently self-funding. Continued cash burn can constrain investment flexibility and leave profitability dependent on sustained growth and further operating leverage.
Moderating Product GrowthFlat year-to-date product revenue suggests that growth is uneven across Cryoport’s business lines. If product momentum remains subdued, it could limit consolidated expansion and make the company more reliant on services growth while newer offerings continue to scale.
Slow Ramp Of Newer InitiativesIntegriCell and the China strategy offer longer-term opportunities, but their near-term contribution is expected to remain limited. Adoption, regulatory, and operational ramp requirements therefore reduce the likelihood that these initiatives will materially offset weaker areas within the next several quarters.
CKX FAQ
What was CryoPort Inc’s price range in the past 12 months?
CryoPort Inc lowest stock price was €6.50 and its highest was €16.30 in the past 12 months.
What is CryoPort Inc’s market cap?
CryoPort Inc’s market cap is €835.62M.
When is CryoPort Inc’s upcoming earnings report date?
CryoPort Inc’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were CryoPort Inc’s earnings last quarter?
CryoPort Inc released its earnings results on Aug 06, 2026. The company reported -€0.178 earnings per share for the quarter, missing the consensus estimate of -€0.172 by -€0.006.
Is CryoPort Inc overvalued?
According to Wall Street analysts CryoPort Inc’s price is currently Undervalued.
Does CryoPort Inc pay dividends?
CryoPort Inc does not currently pay dividends.
What is CryoPort Inc’s EPS estimate?
CryoPort Inc’s EPS estimate is -0.16.
How many shares outstanding does CryoPort Inc have?
CryoPort Inc has 50,649,100 shares outstanding.
What happened to CryoPort Inc’s price movement after its last earnings report?
CryoPort Inc reported an EPS of -€0.178 in its last earnings report, missing expectations of -€0.172. Following the earnings report the stock price went down -0.769%.
Which hedge fund is a major shareholder of CryoPort Inc?
Currently, no hedge funds are holding shares in DE:CKX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CryoPort Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.70 (32.61% Upside)
€18.70 (32.61% Upside)
Blogger Sentiment
Bullish
DE:CKX Sentiment 75%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.53%
12-Months-Change
Fundamentals
Return on Equity
-7.25%
Trailing 12-Months
Asset Growth
-2.29%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CryoPort Inc
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
CKX Company Deck
CKX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated solid operational and financial progress: revenue growth (total and segment-level), expansion of clinical and commercial support, positive adjusted EBITDA and improved operating cash flow, product launches and facility expansions, and active digital/AI initiatives. Headwinds were largely cautious and strategic rather than acute — management reiterated guidance due to macro/geopolitical uncertainty, product growth is moderating YTD, China contribution remains small, and newer offerings like IntegriCell will take time to scale. On balance, the positive metrics and milestones outweigh the cautions, but the company remains prudent in guidance and execution timelines.View all DE:CKX earnings summariesCKX Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€18.70
▲(32.61% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month






